Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
Marwa S Hamza,1 Samia A Shouman,2 Raafat Abdelfattah,3 Heba S Moussa,4 Mervat M Omran2 1Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt; 2Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo Universi...
Saved in:
Main Authors: | Hamza MS (Author), Shouman SA (Author), Abdelfattah R (Author), Moussa HS (Author), Omran MM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters
by: Mervat M. Omran, MD, et al.
Published: (2022) -
PDGFR-β mediated growth failure in pediatric CML cases on Imatinib
by: Prakamya Gupta, et al.
Published: (2020) -
The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2019) -
CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML
by: An-Ni Zhong, et al.
Published: (2021) -
Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India
by: Sudha Sazawal, et al.
Published: (2019)